To further scrutinize the translational potential of GLP-1–MK-801, we benchmarked it against semaglutide, a pharmacokinetically optimized GLP-1 receptor agonist approved for treatment of obesity and clinically available as a once-weekly injectable33. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.